Erasca Inc. Common Stock

Erasca Inc. a clinical-stage biopharmaceutical company focuses on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007 an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer colorectal cancer and acute myeloid leukemia; and ERAS-601 an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801 a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego California.